MFDS approves CJ HealthCare’s acid reflux treatment ‘K-Cab Tab’ as new drug
CJ HealthCare;s acid reflux treatment ‘K-Cab Tab’ acquired approval as a Korean new drug.
The Ministry of Food and Drug Safety(MFDS) acquired approval of CJ HealthCare’s acid reflux treatment ‘K-Cab Tab 50mg(generic name: tegoprazan)’ as a Korean new drug on 5 July.
Indications of the drug appr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
